moneyheap
ARKG · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is ARK Genomic Revolution ETF (ARKG) stock moving?
ARKG rallied from a 47.87 close on Oct 22 to a 55.11 close on Oct 29, then reversed. The Oct 30 session closed at 51.40 on heavy volume of 10.97M shares, the largest in the window. Since then the ETF has made lower highs (55.86 on Oct 29, 54.00 on Oct 30, 52.28 on Nov 2, 50.80 on Nov 3, 50.44 on Nov 4, 48.76 on Nov 9). It fell to a 44.62 close on Nov 5 on 7.56M shares, which is a 19% decline from the Oct 29 close. A partial rebound to 48.25 on Nov 9 faded to 46.27 on Nov 10, which closed below that session's 46.52 VWAP. The price action leans weak and the trend has shifted from rising to sideways-to-down, but the Nov 10 low of 45.78 held above the Nov 5 low of 43.89. The only news item is a Benzinga mention of a SwingTrader sale, which adds little evidence. No fundamental, fund-flow, or holdings news is available in the filings window, so the view rests mainly on price and volume.
News behind the analysis
- Watching ARK Genomic Revolution; Hearing Investor Business Daily SwingTrader Sells StockBenzinga flagged ARKG alongside a report that an Investor Business Daily SwingTrader sold the stock. The item gives no fund-specific or company-specific detail.
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF from ARK Invest, Cathie Wood's firm. It holds a concentrated portfolio of roughly 35 companies working on genomics: gene editing, DNA sequencing, molecular diagnostics and AI-driven drug discovery. Since it launched in 2014 it has been one of the most volatile funds in health care.
How the fund works
ARKG doesn't track an index. ARK's managers pick stocks they think will benefit from the genomics revolution and put at least 80% of assets into them. The portfolio is concentrated, with the top 10 holdings making up roughly 58% of assets. Recent large positions include 10x Genomics, Twist Bioscience, Tempus AI, CRISPR Therapeutics, Natera and Illumina. The expense ratio is 0.75% and assets are roughly $2 billion. Many holdings are small, unprofitable biotech companies, so the fund carries high volatility (beta around 1.7) and risk tied to individual stocks and to the managers' choices.
What usually moves ARKG
- Interest rates and appetite for risky growth stocks
- Clinical trial results and FDA decisions for holdings
- Biotech funding and M&A activity
- Sentiment around AI in drug discovery
- Big moves in top holdings like TXG, TWST, TEM